- Home
- RMM vs LCTX Comparison
RMM vs LCTX Comparison
Compare RMM & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMM
- LCTX
- Stock Information
- Founded
- RMM 2019
- LCTX 1990
- Country
- RMM United States
- LCTX United States
- Employees
- RMM N/A
- LCTX N/A
- Industry
- RMM Trusts Except Educational Religious and Charitable
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RMM Finance
- LCTX Health Care
- Exchange
- RMM Nasdaq
- LCTX Nasdaq
- Market Cap
- RMM 276.0M
- LCTX 274.0M
- IPO Year
- RMM N/A
- LCTX N/A
- Fundamental
- Price
- RMM $14.00
- LCTX $1.74
- Analyst Decision
- RMM
- LCTX Strong Buy
- Analyst Count
- RMM 0
- LCTX 4
- Target Price
- RMM N/A
- LCTX $4.25
- AVG Volume (30 Days)
- RMM 66.5K
- LCTX 2.0M
- Earning Date
- RMM 01-01-0001
- LCTX 11-06-2025
- Dividend Yield
- RMM 7.33%
- LCTX N/A
- EPS Growth
- RMM N/A
- LCTX N/A
- EPS
- RMM 0.96
- LCTX N/A
- Revenue
- RMM N/A
- LCTX $10,816,000.00
- Revenue This Year
- RMM N/A
- LCTX N/A
- Revenue Next Year
- RMM N/A
- LCTX $176.00
- P/E Ratio
- RMM $15.55
- LCTX N/A
- Revenue Growth
- RMM N/A
- LCTX 24.05
- 52 Week Low
- RMM $12.32
- LCTX $0.37
- 52 Week High
- RMM $16.10
- LCTX $2.09
- Technical
- Relative Strength Index (RSI)
- RMM 47.09
- LCTX 50.21
- Support Level
- RMM $14.03
- LCTX $1.66
- Resistance Level
- RMM $14.20
- LCTX $2.09
- Average True Range (ATR)
- RMM 0.13
- LCTX 0.13
- MACD
- RMM -0.01
- LCTX -0.01
- Stochastic Oscillator
- RMM 45.00
- LCTX 33.04
About RMM RiverNorth Managed Duration Municipal Income Fund Inc.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.